Chorea Gravidarum Medication

  • Author: Tarakad S Ramachandran, MBBS, FRCP(C), FACP; Chief Editor: Selim R Benbadis, MD   more...
 
Updated: Feb 3, 2012
 

Medication Summary

The goals of pharmacotherapy are to reduce morbidity and prevent complications.

Next

Antipsychotic agents

Class Summary

These agents are useful, perhaps owing to their sedating properties.

Haloperidol (Haldol, Haldol Decanoate, Halperon)

 

Antipsychotic and strong tranquilizer; butyrophenone used in treatment of acute psychosis, acute schizophrenia, manic phases, control of aggression, agitation, and disorganized and psychotic thinking. May be used to help treat false perceptions (eg, hallucinations, delusions), Gilles de la Tourette syndrome, and psychosis associated with dementia, depressions, or mania.

More likely to cause adverse effects such as tardive dyskinesia than most other antipsychotic drugs.

Risperidone (Risperdal)

 

Benzisoxazole derivative, novel antipsychotic drug. Well absorbed after PO administration, has high bioavailability, and exhibits dose proportionality in therapeutic dose range, although interindividual plasma concentrations vary considerably. Food does not affect extent of absorption, thus can be administered with or without meals.

Peak plasma concentrations of parent drug reached within 1-2 h after intake. Mainly metabolized via hydroxylation and oxidative N-dealkylation. Major metabolite is 9-hydroxy-risperidone, which has similar activity to parent drug; clinical effect brought about by active moiety, namely risperidone plus 9-hydroxy-risperidone.

Hydroxylation depends on debrisoquine 4-hydroxylase (ie, metabolism of risperidone is sensitive to debrisoquine hydroxylation-type genetic polymorphism). Consequently, concentrations of parent drug and active metabolite differ substantially in extensive and poor metabolizers. However, concentration of active moiety (risperidone plus 9-hydroxy-risperidone) did not differ substantially between extensive and poor metabolizers, and elimination half-lives were similar in all subjects (approximately 20-24 h).

Rapidly distributed. Volume of distribution 1-2 L/kg. Steady-state concentrations of risperidone and active moiety were reached within 1-2 d and 5-6 d, respectively. In plasma, bound to albumin and alpha1-acid glycoprotein. Plasma protein binding of risperidone is approximately 88% and that of metabolite 77%. One wk after administration, 70% of dose excreted in urine and 14% in feces. In urine, risperidone plus 9-hydroxy-risperidone represents 35-45% of dose. Remainder is inactive metabolites.

Evaluated at dose range of 1-16 mg/d PO and compared to both placebo and haloperidol, studies indicated that risperidone is an effective antipsychotic agent improving both positive and negative symptoms.

Pimozide (Orap)

 

Diphenylbutylpiperidine derivative with neuroleptic properties. Relatively nonsedating and can be administered in single daily dose.

Appears to have selective ability to block central dopaminergic receptors, although it affects norepinephrine turnover at higher doses. Extrapyramidal effects also are observed, but it appears to have fewer autonomic effects. Peak plasma level in humans occurs 3-8 h after administration, and plasma levels decrease slowly to approximately 50% of peak level at 48-72 h after dosing.

Used to suppress severe motor and phonic tics in patients with Tourette disorder whose symptoms have not responded satisfactorily to standard treatment (eg, haloperidol). Use also extended to management of manifestations of chronic schizophrenia in which main manifestations do not include excitement, agitation, or hyperactivity. Not indicated in treatment of patients with mania or acute schizophrenia.

Previous
Next

Anticonvulsants

Class Summary

These agents have proven useful in the management of severe muscle spasms and provide sedation.

Chloral hydrate (Noctec, Aquachloral)

 

Hypnotic and anxiolytic. At normal doses, this sleep induction does not affect breathing, blood pressure, or reflexes. When used in combination with analgesics, can help manage pain after surgery. Used for sedation for procedures (eg, CT scan) or for agitation that is interfering with ventilation.

Onset of action is 10-15 min. Metabolized to an active metabolite, trichloroethanol, which is excreted by kidney after conjugation to glucuronide salt. Plasma life is 8-64 h in neonates (mean 37 h). Protein binding is approximately 40%.

Available as supp, syr, or cap; mix syr with one-half glass (4 oz) water or fruit juice to minimize GI upset; cap should be swallowed whole followed by full glass (8 oz) of water or fruit juice.

Phenobarbital (Barbita, Solfoton, Luminal)

 

Barbiturate mostly used as anticonvulsant. Usually used in treatment of grand mal and focal motor epilepsy. In addition, used prophylactically for febrile seizures in children. Exact mode and site of action of phenobarbital (and other barbiturates) in suppression of seizure activity unknown. Believed to work by reducing neuronal excitability and by increasing motor cortex threshold to electrical stimulation.

Use also extends to suppression of anxiety and apprehension.

Valproic acid (Depakote, Depakene)

 

Anticonvulsant whose activity may be related to increased brain concentrations of GABA. Peak serum levels occur approximately 1-4 h after single PO dose. Serum half-life typically 6-16 h. Primarily metabolized in liver to glucuronide conjugate. Elimination of valproic acid and its metabolites occur principally in urine, with minor amounts in feces and expired air.

Used as sole or adjunctive therapy in treatment of simple or complex absence seizures, including petit mal, and useful in primary generalized seizures with tonic-clonic manifestations. Also used for manic phase of depression and in migraine.

Carbamazepine (Tegretol)

 

Chemically similar to cyclic antidepressants. Also manifests antimanic, antineuralgic, antidiuretic, anticholinergic, antiarrhythmic, and antipsychotic effects. Anticonvulsant action not known but may involve depressing activity in nucleus ventralis anterior of thalamus, resulting in reduction of polysynaptic responses and blocking posttetanic potentiation. Due to potentially serious blood dyscrasias, undertake benefit-to-risk evaluation before drug instituted. Peak serum levels in 4-5 h. Half-life (serum) in 12-17 h with repeated doses. Therapeutic serum levels are 4-12 mcg/mL. Metabolized in liver to active metabolite (ie, epoxide derivative) with half-life of 5-8 h. Metabolites excreted through feces and urine.

Previous
Next

Antiemetics

Class Summary

These agents are used to control symptomatic nausea and may have antipsychotic effects.

Chlorpromazine (Ormazine, Thorazine)

 

Blocks postsynaptic mesolimbic dopamine receptors, has anticholinergic effects, and depresses reticular activating system. Blocks alpha-adrenergic receptors and depresses release of hypophyseal and hypothalamic hormones.

Previous
Next

Benzodiazepines

Class Summary

By binding to specific receptor sites, these agents appear to potentiate effects of GABA and facilitate inhibitory GABA neurotransmission and other inhibitory transmitters.

Diazepam (Valium)

 

Anxiolytic sedative drug useful in symptomatic relief of anxiety and tension states. Also has adjunctive value in relief of certain neurospastic conditions. Peak blood levels reached within 1-2 h after single PO dosing. Acute half-life is 6-8 h with slower decline thereafter, possibly due to tissue storage. However, after repeated doses, blood levels increase significantly over 24-48 h.

In humans, comparable blood levels were obtained in maternal and cord blood, indicating placental transfer of drug.

Symptomatic management of mild-to-moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear, or aggressiveness, such as may occur in psychoneurosis, anxiety reactions due to stress conditions, and anxiety states with somatic expression.

In acute alcohol withdrawal, may be useful in symptomatic relief of acute agitation, tremor, and impending acute delirium tremens.

As adjunct for relief of skeletal muscle spasm due to reflex spasm to local pathology, such as inflammation of muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and rare "stiff man syndrome."

While usual daily dosages meet needs of most patients, some may require higher doses. In first few days of administration, cumulative effect may occur; therefore, increase dosage only after stabilization is apparent.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Tarakad S Ramachandran, MBBS, FRCP(C), FACP  Professor of Neurology, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Chair, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, FRCP(C), FACP is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners, American College of International Physicians, American College of Managed Care Medicine, American College of Physicians, American Heart Association, American Stroke Association, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, and Royal Society of Medicine

Disclosure: Abbott Labs None None; Teva Marion None None; Boeringer-Ingelheim Honoraria Speaking and teaching

Specialty Editor Board

Stephen T Gancher, MD  Adjunct Associate Professor, Department of Neurology, Oregon Health Sciences University

Stephen T Gancher, MD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, and Movement Disorders Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Nestor Galvez-Jimenez, MD, MSc, MHA  Chairman, Department of Neurology, Program Director, Movement Disorders, Department of Neurology, Division of Medicine, Cleveland Clinic Florida

Nestor Galvez-Jimenez, MD, MSc, MHA is a member of the following medical societies: American Academy of Neurology, American College of Physicians, and Movement Disorders Society

Disclosure: Nothing to disclose.

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Chief Editor

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

References
  1. Kranick SM, Mowry EM, Colcher A, Horn S, Golbe LI. Movement disorders and pregnancy: a review of the literature. Mov Disord. Apr 30 2010;25(6):665-71. [Medline].

  2. Willson P, Preece AA. Chorea gravidarum. Arch Intern Med. 1932;49:471-533, 671-697.

  3. Zegart KN, Schwarz RH. Chorea gravidarum. Obstet Gynecol. Jul 1968;32(1):24-7. [Medline].

  4. Dike GL. Chorea gravidarum: a case report and review. Md Med J. Sep 1997;46(8):436-9. [Medline].

  5. Greenfield JG, Wolfsohn JM. The pathology of Sydenham's chorea. Lancet. 1922;2:603-606.

  6. Winkelman NW, Eckel JL. The brain in acute rheumatic fever. Arch Neurol Psych. 1932;28:844-870.

  7. Unno S, Iijima M, Osawa M, et al. [A case of chorea gravidarum with moyamoya disease]. Rinsho Shinkeigaku. Apr 2000;40(4):378-82. [Medline].

  8. Koide R, Sakamoto M, Tanaka K, Hayashi H. Opsoclonus-myoclonus syndrome during pregnancy. J Neuroophthalmol. Sep 2004;24(3):273. [Medline].

  9. Black M. Two cases of chorea in pregnancy. Glasgow Med J. 1900;441-444.

  10. Matthews AA. Chorea complicating pregnancy. Northwest Med. 1911;15:372.

  11. Taranta A, Stollerman GH. The relationship of Sydenham's chorea to infection with group A streptococci. Am J Med. Feb 1956;20(2):170-5. [Medline].

  12. TARANTA A. Relation of isolated recurrences of Sydenham's chorea to preceding streptococcal infections. N Engl J Med. Jun 11 1959;260(24):1204-10. [Medline].

  13. Jonas S, Spagnuolo M, Kloth HH. Chorea gravidarum and streptococcal infection. Obstet Gynecol. Jan 1972;39(1):77-9. [Medline].

  14. ARON AM, FREEMAN JM, CARTER S. THE NATURAL HISTORY OF SYDENHAM'S CHOREA. REVIEW OF THE LITERATURE AND LONG-TERM EVALUATION WITH EMPHASIS ON CARDIAC SEQUELAE. Am J Med. Jan 1965;38:83-95. [Medline].

  15. Warren HA, Chornyak J. Cerebral manifestations of acute rheumatic fever. Arch Int Med. 1947;79:589-601.

  16. CHUN RW, SMITH NJ, FORSTER FM. Papilledema in Sydenham's chorea. Am J Dis Child. May 1961;101:641-4. [Medline].

  17. Usher SJ, Jasper HH. The etiology of Sydenham's chorea:electroencephalographic studies. CMAJ. 1941;44:365-371.

  18. Buchanan DN, Walker AE, Case TJ. The pathogenesis of chorea. J Pediatr. 1942;20:555-575.

  19. Miranda M, Cardoso F, Giovannoni G, Church A. Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry. Feb 2004;75(2):327-8. [Medline].

  20. Dale RC. Autoimmunity and the basal ganglia: new insights into old diseases. QJM. Mar 2003;96(3):183-91. [Medline].

  21. Archelos JJ, Hartung HP. Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci. Jul 2000;23(7):317-27. [Medline].

  22. Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol. Nov 2007;7(6):360-73. [Medline].

  23. Brett WR. Some paediatric eponyms: IV. Sydenham's Chorea. Br J Child Dis. 1932;29:283.

  24. Marques-Dias MJ, Mercadante MT, Tucker D, Lombroso P. Sydenham's chorea. Psychiatr Clin North Am. Dec 1997;20(4):809-20. [Medline].

  25. Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies in movement disorders. Pediatrics. Jul 1993;92(1):39-43. [Medline].

  26. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. Feb 1998;155(2):264-71. [Medline].

  27. Dale RC, Church AJ, Surtees RA, et al. Post-streptococcal autoimmune neuropsychiatric disease presenting as paroxysmal dystonic choreoathetosis. Mov Disord. Jul 2002;17(4):817-20. [Medline].

  28. Alvarenga PG, Hounie AG, Mercadante MT, Diniz JB, Salem M, Spina G, et al. Obsessive-compulsive symptoms in heart disease patients with and without history of rheumatic fever. J Neuropsychiatry Clin Neurosci. Summer 2006;18(3):405-8. [Medline].

  29. Korn-Lubetzki I, Brand A, Steiner I. Recurrence of Sydenham chorea: implications for pathogenesis. Arch Neurol. Aug 2004;61(8):1261-4. [Medline].

  30. Rote NS, Dostal-Johnson D, Branch DW. Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. Am J Obstet Gynecol. Aug 1990;163(2):575-84. [Medline].

  31. Triplet DA. New diagnostic strategies for lupus anticoagulants and antiphospholipid antibodies. Haemostasis. May-Jun 1994;24(3):155-64. [Medline].

  32. Ramsey-Goldman R, Kutzer JE, Kuller LH, et al. Previous pregnancy outcome is an important determinant of subsequent pregnancy outcome in women with systemic lupus erythematosus. Am J Reprod Immunol. Oct-Dec 1992;28(3-4):195-8. [Medline].

  33. Kilpatrick DC, Maclean C, Liston WA, Johnstone FD. Anti-phospholipid antibody syndrome and pre-eclampsia. Lancet. Oct 21 1989;2(8669):987-8. [Medline].

  34. Roubey RA. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood. Nov 1 1994;84(9):2854-67. [Medline].

  35. Qasim A. An unusual case of chorea gravidarum. Postgrad Med J. Jun 2000;76(896):374, 378-9. [Medline].

  36. Asherson RA, Cervera R, Merrill JT, Erkan D. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost. Apr 2008;34(3):256-66. [Medline].

  37. Kim, Ok; Kim, A; Seo, M W; Kweon, J Y; Ahn, H Y; Park, et al. Chorea gravidarum associated with Moyamoya disease. J Perinatal Med. 2007;35(Suppl II):S187.

  38. Husby G, van de Rijn I, Zabriskie JB, et al. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med. Oct 1 1976;144(4):1094-110. [Medline].

  39. Ichikawa K, Kim RC, Givelber H, Collins GH. Chorea gravidarum. Report of a fatal case with neuropathological observations. Arch Neurol. Jul 1980;37(7):429-32. [Medline].

  40. Axley J. Rheumatic chorea controlled with haloperidol. J Pediatr. Dec 1972;81(6):1216-7. [Medline].

  41. Shenker DM, Grossman HJ, Klawans HL. Treatment of Sydenham's chorea with haloperidol. Dev Med Child Neurol. Feb 1973;15(1):19-24. [Medline].

  42. Patterson JF. Treatment of chorea gravidarum with haloperidol. South Med J. Sep 1979;72(9):1220-1. [Medline].

  43. Donaldson JO. Control of chorea gravidarum with haloperidol. Obstet Gynecol. Mar 1982;59(3):381-2. [Medline].

  44. Magnier P. [Apropos of vomiting in pregnancy: therapeutic study of R 1625]. Gynecol Prat. 1964;15(1):17-23. [Medline].

  45. Van Waes A, Van de Velde E. Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol. 1969;9:224.

  46. Shannon KM, Fenichel GM. Pimozide treatment of Sydenham's chorea. Neurology. Jan 1990;40(1):186. [Medline].

  47. Pallares AJ, Hurtado L. (Translated title) Carbamazepine in paroxysmal choreoathetosis in Sydenham's chorea. An Esp Pediatr (Anales espanoles pediatrica). 1989;30 (1):41-44.

  48. Pulsinelli WA, Hamill RW. Chorea complicating oral contraceptive therapy. Case report and review of the literature. Am J Med. Sep 1978;65(3):557-9. [Medline].

  49. Nausieda PA, Koller WC, Weiner WJ, Klawans HL. Chorea induced by oral contraceptives. Neurology. Dec 1979;29(12):1605-9. [Medline].

  50. Beresford OD, Graham AM. Chorea gravidarum. J Obstet Gynaecol Br Emp. Aug 1950;57(4):616-25. [Medline].

  51. Fleischman MJ. A case report of chorea gravidarum complicating five pregnancies. Am J Obstet Gynecol. Dec 1953;66(6):1328-30. [Medline].

  52. Ghanem Q. Recurrent chorea gravidarum in four pregnancies. Can J Neurol Sci. May 1985;12(2):136-8. [Medline].

  53. BEAN WB, COGSWELL R. Vascular changes of the skin in pregnancy; vascular spiders and palmar erythema. Surg Gynecol Obstet. Jun 1949;88(6):739-52. [Medline].

  54. Cardoso F, Eduardo C, Silva AP, Mota CC. Chorea in fifty consecutive patients with rheumatic fever. Mov Disord. Sep 1997;12(5):701-3. [Medline].

  55. Donaldson JO. Movement disorders. In: Neurology of Pregnancy. Major Problems In Neurology. Vol 7. Philadelphia: WB Saunders Co; 1978:87-97.

  56. Forrest AD, Hales IB. Severe chorea gravidarum treated with corticotrophin. Lancet. Oct 27 1956;271(6948):874-5. [Medline].

  57. Markham CH, Ansel RD. Drugs and motor behaviour. In: Jarvik ME, ed. Psychopharmacology in the Practice of Medicine. NY: Appleton Century Crofts; 1977:127-139.

  58. Wall C, Andrews HR. On chorea in pregnancy. J Obstet Gynaecol Br. 1903;3:540-547.

  59. Winkelbauer RG, Kimsey LR. Chorea gravidarum treated with chlorpromazine; case report. Am J Obstet Gynecol. Jun 1956;71(6):1353-4. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.